✦ LIBER ✦

Survival and recurrence free benefits with different lymphadenectomy for resectable gastric cancer: A meta-analysis

✍ Scribed by Jiang, Lei; Yang, Ke-Hu; Guan, Quan-Lin; Zhao, Peng; Chen, Yan; Tian, Jin-Hui

Book ID: 120457142
Publisher: John Wiley and Sons
Year: 2013
Tongue: English
Weight: 385 KB
Volume: 107
Category: Article
ISSN: 0022-4790
DOI: 10.1002/jso.23325

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Progression-Free Survival as a Surrogate

Progression-Free Survival as a Surrogate for Overall Survival in Advanced/Recurrent Gastric Cancer Trials: A Meta-Analysis

✍ Paoletti, X.; Oba, K.; Bang, Y.-J.; Bleiberg, H.; Boku, N.; Bouche, O.; Catalano 📂 Article 📅 2013 🏛 Oxford University Press 🌐 English ⚖ 313 KB

Is the sentinel node biopsy clinically a

Is the sentinel node biopsy clinically applicable for limited lymphadenectomy and modified gastric resection in gastric cancer? A meta-analysis of feasibility studies

✍ Keun Won Ryu; Bang Wool Eom; Byung-Ho Nam; Jun Ho Lee; Myeong Cherl Kook; Il Ju 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 159 KB

## Abstract ## Background: Sentinel node biopsies (SNBs) have been clinically applied in melanoma and breast cancer for limited lymphadenectomy. However, the use of SNB remains controversial in gastric cancer due to unsatisfactory sensitivity and variability. This meta‐analysis was performed to de

Survival and disease-progression benefit

Survival and disease-progression benefits with treatment regimens for advanced colorectal cancer: a meta-analysis

✍ Vassilis Golfinopoulos; Georgia Salanti; Nicholas Pavlidis; John PA Ioannidis 📂 Article 📅 2007 🏛 The Lancet 🌐 English ⚖ 223 KB

Progression-Free Survival with Fulvestra

Progression-Free Survival with Fulvestrant 500 mg and Alternative Endocrine Therapies as Second-Line Treatment for Advanced Breast Cancer: A Network Meta-Analysis with Parametric Survival Models

✍ Cope, Shannon; Ouwens, Mario J.N.M.; Jansen, Jeroen P.; Schmid, Peter 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 928 KB

Immunochemotherapy with OK-432 may impro

Immunochemotherapy with OK-432 may improve survival for people with curatively resected gastric cancer: Abstracted from: Sakamoto J, Teramukai S, Nakazato H et al. Efficacy of adjuvant immunochemotherapy with OK-432 for patients with curatively resected gastric cancer: a meta-analysis of centrally randomized controlled clinical trials. Journal of Immunotherapy 2002; 25: 405–12.

✍ Ilaria Panzini; Lorenzo Gianni; Davide Tassinari 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 67 KB

Pre-operative chemo-radiotherapy improve

Pre-operative chemo-radiotherapy improves 3-year survival in people with resectable oesophageal cancer: Abstracted from: Urschel JD, Vasan H. A meta-analysis of randomized controlled trials that compared neoadjuvant chemo-radiation and surgery to surgery alone for resectable esophageal cancer. Am J Surg 2003;185:538–43

✍ P Naughton; T.N Walsh 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 149 KB